GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Clover Biopharmaceuticals 2197.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

1.42

+5.19%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥4.0m

FY2019FY2025

Net income

−CN¥232.7m

FY2019FY2025

Free cash flow

−CN¥221.9m

FY2019FY2025

Shareholders' equity

−CN¥2.09bn

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
RevenueCN¥4.0mCN¥44.7mCN¥45.7m——CN¥668,454CN¥153,721
Research and developmentCN¥181.1mCN¥213.6mCN¥756.8mCN¥1.71bnCN¥2.13bnCN¥265.8mCN¥53.3m
Operating income−CN¥288.5m−CN¥1.11bn−CN¥3.00bn−CN¥2.74bn−CN¥2.61bn−CN¥354.8m−CN¥44.5m
Net income−CN¥232.7m−CN¥1.05bn−CN¥161.3m−CN¥2.86bn−CN¥7.01bn−CN¥1.07bn−CN¥56.6m
Diluted earnings per share-0.18-0.84-0.13-2.55-6.05-0.92-0.05

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsCN¥533.5mCN¥946.5mCN¥2.45bnCN¥5.47bnCN¥6.23bnCN¥1.38bnCN¥216.9m
Cash and short-term investmentsCN¥333.2mCN¥497.9mCN¥892.3mCN¥1.91bnCN¥3.34bnCN¥939.2mCN¥184.8m
Total liabilitiesCN¥2.63bnCN¥2.85bnCN¥3.30bnCN¥6.25bnCN¥4.81bnCN¥2.53bnCN¥295.8m
DebtCN¥24.7mCN¥89.6mCN¥334.5mCN¥354.4mCN¥67.9mCN¥1.15bnCN¥211.2m
Shareholders' equity−CN¥2.09bn−CN¥1.91bn−CN¥853.4m−CN¥778.1mCN¥1.42bn−CN¥1.14bn−CN¥79.0m
Shares outstanding1,261m1,255m1,247m1,118m1,158m1,158m1,158m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−CN¥221.9m−CN¥336.0m−CN¥847.7m−CN¥1.97bn−CN¥1.07bnCN¥555.4m−CN¥31.0m
Capital spending−CN¥37,436−CN¥1.9m−CN¥10.7m−CN¥122.9m−CN¥93.5m−CN¥132.5m−CN¥7.9m
Free cash flow−CN¥221.9m−CN¥337.9m−CN¥858.3m−CN¥2.09bn−CN¥1.16bnCN¥422.9m−CN¥38.9m
Dividends paid————−CN¥117.1m——

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥205,576CN¥287,425CN¥3.8mCN¥56.5m−CN¥11.8mCN¥45.4mCN¥299,290—
Operating income−CN¥163.3m−CN¥156.6m−CN¥132.9m−CN¥924.5m−CN¥183.2m−CN¥957.7m−CN¥2.05bn−CN¥1.50bn
Net incomeCN¥1.10bn−CN¥114.7m−CN¥117.9m−CN¥941.3m−CN¥110.8m−CN¥919.0mCN¥757.7m−CN¥1.53bn
Diluted earnings per share0.85-0.09-0.09-0.75-0.09-0.740.61-1.37
Cash from operations—−CN¥92.0m−CN¥135.0m−CN¥152.0m−CN¥183.0m−CN¥346.0m−CN¥501.0m−CN¥1.32bn
Capital spending————−CN¥1.0m−CN¥3.0m−CN¥4.0m−CN¥28.0m
Free cash flow————−CN¥184.0m−CN¥349.0m−CN¥505.0m−CN¥1.35bn
Total assetsCN¥281.6mCN¥533.5mCN¥692.0mCN¥946.5mCN¥2.09bnCN¥2.45bnCN¥3.59bnCN¥5.47bn
Cash and short-term investmentsCN¥122.0mCN¥333.2mCN¥460.9mCN¥497.9mCN¥578.6mCN¥892.3mCN¥1.51bnCN¥1.91bn
DebtCN¥2.4mCN¥12.4mCN¥15.2mCN¥104.4mCN¥269.1mCN¥389.5mCN¥531.0mCN¥412.7m
Shareholders' equity−CN¥932.9m−CN¥2.09bn−CN¥1.99bn−CN¥1.91bn−CN¥969.8m−CN¥853.4mCN¥33.3m−CN¥778.1m

Financial ratios

Data as of 27 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-7256.4%-2485.3%-305.2%——-58642.3%-47601.5%
Net margin-5851.4%-2351.5%-352.9%——-159559.4%-36805.3%
Return on equity11.1%55.2%18.9%366.9%-493.6%93.2%—
Return on assets-43.6%-111.2%-6.6%-52.2%-112.6%-77.1%—
Free cash flow yield-12.5%-18.9%-47.6%-117.2%-59.8%42.2%—
Revenue growth-91.1%-2.1%———334.8%—
Earnings growth-77.9%552.1%-94.3%-59.3%557.1%1785.2%—
Current ratio0.19x0.35x0.83x1.55x2.36x15.71x—
Debt to equity-0.01x-0.05x-0.45x-0.48x0.04x-1.15x—
Equity ratio-392.5%-201.3%-34.9%-14.2%22.8%-82.8%—
Interest coverage-674.64x-165.89x-6.40x-404.76x-888.38x-113.22x—
R&D as a share of sales4554.2%477.3%1655.5%——39759.4%34696.2%
Buybacks as a share of market value-0.5%-0.7%-11.5%3.5%0.0%0.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue—42.8%—
Operating income-52.8%-4.1%—
Net income-56.6%-26.3%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-2866.0%———
Net margin-2637.2%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-11.0-0.3-4.2-0.9-1.9
Price to sales—5.914.6——

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.